Segundo Mesa Castillo. As Specialist in Neurology, he worked for 10 years in the Institute of Neurology of Havana, Cuba. He has worked in Electron Microscopic Studies on Schizophrenia for 32 years.
Arvind graduated in Veterinary Medicine with specialization in Veterinary Microbiology (MVSc) from India. Following early years in mixed Veterinary practice, he served as Assistant Professor Veterinary Microbiology in the Vet School Palampur HP, India. He started his career in infection and immunity research with Masters in Immunology from Imperial College School of Medicine, London and PhD in Veterinary Microbiology from University of Edinburgh (UK) in 2005. He was hired by Lohmann Animal Health GmbH as Director Research based in Hannover, Germany from 2012-15. After merger with Elanco Animal Health, he served as Director Research Poultry Vaccines (EU) based in Germany. In 2016, He moved to the US in the Global Vaccine Research team, as Leader Bacteriology - Vaccine Research Centre Elanco Animal Health, based in Indianapolis. Currently, he is serving as Research Advisor and Leader – Discovery Biology Research (Bacteriology & Parasitology) ERL, Global Research and External Innovation, at the Elanco Global Headquarters in Indiana.
Angus Dalgleish qualified in medicine from University College London and trained in internal medicine and medical oncology in Brisbane and Sydney. He did his MD with Professor Robin Weiss at the ICR before becoming a Senior Clinical Fellow at the MRC Clinical Research Centre. Since 1992 he has been Professor of Oncology at St. George’s. He has over 370 publications and has co-authored 5 books and been an editorial member of many oncology and immunology journals.
She had her Bachelor of Veterinary Medical science Cairo University 1992, MSc of Virology Cairo University 1999 and PhD in Virology Cairo University2004. She promoted to Associate professor in 2009 then to Professor of Virology and Immunology 2014 at the National Research Centre (NRC). She has a special interest in Molecular Virology; currently she is working on several viruses which cause great economic losses such as FMD, BVD, ND, IB, ILT and reemerging viral diseases such as Bluetongue. In addition, she has several researches on diagnosis and control of these viruses. She has been principle investigator for many projects funded by NRC and STDF. She has supervised many MSc and PhD thesis and a chief Editor in many national and international Journals; she is also a member of many national and international specified associations. She is a member of the Biosafety and Biorisk committee and CEO of the Virology Unit in the Department of Microbiology at the NRC.
He has linked discovery with the generation of new vaccine and immunotherapeutic approaches in infectious diseases, cancer and type 1 diabetes.
Consultant of clinical microbiology and immunology, Researcher at clinical and chemical pathology department, National research center,Egypt. Member of molecular laboratory center of excellence, National research Centre. Working in one of private megalabs (El mokhtaber laboratory in Egypt) as clinical microbiologist. Shared in several internationally funded community projects as Alleviating and Managing Anemia induced Therapy for Hepatitis C Patients Title: in Seven Villages of Egypt/ Community outreach approach for having a model of a village controlled from diabetes with improved quality of life: Egypt. Has 13 ongoing projects dealing with genetic background of high socially – economic burden infectious and chronic disease with many published scientific publications in well acclaimed journals.
Through personalized antimicrobial therapy, Detection and assessing AmpC beta lactamase types in Escherichia coli and Klebsiella pneumonia in Egyptian hospitals
Luiz Werber-Bandeira is the Head of clinical and experimental immunology unit - Santa Casa da Misericórdia, Rio de Janeiro - General Hospital. He has a degree in Medicine, post-doctorate in Immuno-Genetics, and PhD in medicine-immunology-dermatology from Federal University of Rio de Janeiro-UFRJ. He is also specialized in Clinical Immunology-Allergy at the Federal University of Rio de Janeiro-UFRJ. Reorganizer of the clinical and experimental immunology unit - Santa Casa da Misericórdia, Rio de Janeiro. Reorganizer of the immunology laboratory of the clinical and experimental immunology unit - Santa Casa da Misericórdia, Rio de Janeiro. Creator, Scientific organizer and president of ImmunoRio in 97, 99, 2001 and 2004. President and scientific organizer of the extra section of clinical immunology 2006, 2007, 2008, 2010, 2015... Organizer and chair of the clinical immunology & chair of the South Fluminense-Vassouras faculty. Full professor in connected Domains-Carlos Chagas medical graduate school.
Founder of IACIB,Bangladesh Professor of Microbiology and Immunology. IACIB has 21 General members with 7 members of its Executive Committee. Professor Dr. Moazzem Hossain, Chairman IACIB, is a specialist in Microbiology, Immunology & Biotechnology with long experience in operation of Govt. & NGO projects. He worked in Directorate General of Health Service, Ministry of Health & Family Welfare as Director Disease Control for long.He received the ‘Vestergaard Frandsen Award 2011’ from the National Academy of Vectors and Vector Borne Diseases, India for the South East Asian region for his outstanding contributions in the field of communicable diseases control in Bangladesh. His work has been appreciated by various national and international bodies.
Immunology,Pathology, Preventive and Personalized Medicine,Cancer Immunology
Dr Ali Mousa Mahdi Al Mousawi has obtained his degree, M.B, Ch.B 1979, M.Sc. (Community Medicine) 1985 and is a Specialist doctor (Community Medicine) Director of the department of Preventive health at the Directorate of Health-Kerbala; from Feb.1985-18 Apr.2003. He is also Deputy general director of Kerbala health directorate 19 Apr. 2003-1 Apr.2005. Till now, he is a Lecturer and Decider of Dept. of Family and Community Medicine Kerbala Medical college 1Apr.2005-2005. He has successfully conducted Training courses: More than eighty training courses and workshops on primary health care programs and community medicine. Dr. Mousawi has done sixty two conference paper presentations in Iraq, Jordon, UK, Italy and Iran and published fifty papers in medical journals.
Manaog Jerlita completed her BS in Nursing at the age of 22 at the Makati Medical Center College of Nursing. She had units and a candidate of Masteral in Clinical Nutrition at the Philippine Women’s University. Manaog J worked as the Assistant Unit Manager at the Operating Room Department (Makati Med Center); a Clinical Instructor at he Makati Medical Center College of Nursing for 9 years and a Hospital and Home based Private Duty Nurse. She leads the research team for the Management Study of Dr. Renato Jose Priela of the Hospital of the Holy Cross entitled: “Promotion of Preventive Healthcare as a Tool in Hospital Patients Satisfaction” presented at the University of the Philippines Masteral of Hospital Administration and Public Health – Manila in 2011. She is one of the 12 selected E.Excel Leader and Speaker as participant for the Speakers Training by Dr. Jau Fei Chen (A World Renowned Scientist and Immunologist and the founder of Nutritional Immunology ) held at the Cebu International Convention Center in 1998 organized and sponsored by E.Excel (Phil's) Inc. for Independent Distributors of E.Excel. E.Excel International is at the forefront in doing research on Nutritional Immunology (N.I.). Currently, Manaog J is a favorite lecturer and conducts numerous speaking engagements in schools, colleges, hospitals, Municipal Health Offices and organizations in Philippines in spreading the Science of N.I. currently; she is the Sole Proprietress of N.I. Calmin the Center for Preventive Healthcare Management and N.I. Awareness for 15 years and a N.I. Advocate since 1997. She is currently the Community Service Director for Mother and Child Care of the Rotary Club of Downtown Calapan District 3820.
Alex Shnyra (born January 05, 1956) received his Doctor of Medicine in 1979 and Doctor of Philosophy in 1985 at Moscow, Russia. Dr. Shnyra was a senior scientist at All-Union Cardiology Research Center at Moscow, a visiting scientist at Dept. of Clinical Bacteriology, Karolinska Institute, Stockholm, Sweden, and he hold Faculty Positions at several medical schools in the U.A.E. and U.S.A. Since 2007, he is an Associate Professor of immunology at Kansas City University of Medicine and Biosciences. Dr. Shnyra is an expert immunologist with extensive experience in cell biology, immunology, molecular biology and biochemistry. He has developed several funded research projects in Russia, Sweden, and UAE and at NIH, USA. Dr. Shnyra is a receiver of International and Nationals awards and honors. His research is cited in more than 800 scientific publications. His current research is focused on the link between autoimmune diseases and the gastrointestinal microbiome.
Dr. Amanda Carter is from the United States of America, and was born in Washington, D.C. She is an only child who was raised in Maryland. She attended Shaw University located in Raleigh, North Carolina for undergraduate studies and successfully completed the required course work in three years with honors with a major in Psychology. Dr. Carter obtained her Masters Degree from Howard University in Washington, D.C. Subsequently, she enrolled into a Doctoral program at Nova Southeastern University located in Fort Lauderdale, Florida and graduated in June 2014. Her dissertation research was conducted in East Haddam, Connecticut which addressed Parental Perceptions for Adolescents diagnosed with Asperger’s Syndrome and/or Autism Spectrum Disorder. Dr. Carter’s area of expertise includes Autism Spectrum Disorder and mental health. In October 2014, she founded Care and Recreational Activities for Autistic People (CARAFAP, LLC). The mission of CARAFAP, LLC is to provide recreational, respite, special events, behavioral, and consulting services for individuals diagnosed with Autism Spectrum Disorder. CARAFAP’s goal is to create a supportive environment where individuals with disabilities are free to be themselves without being pigeonholed by societal norms and expectations. Additionally, CARAFAP incorporates non-traditional and/or unorthodox therapies which include music, dance therapy, and incorporation of animals such as horses and therapy dogs to create supportive environments to enhance an individual’s motivational interest. To date, CARAFAP is a for-profit entity and its sister company, CARAFAP Foundation is an active 501c3 organization. CARAFAP, LLC has employed over 50 staff members since its inception and services clients in DC, MD, VA and abroad. CARAFAP accepts private pay, Medicaid, and clients on the autism waiver in the state of Maryland. CARAFAP has received accolades, numerous awards, recognized by the mayor of Delaware for providing exceptional community-based services, and has received county executive awards in the State of Maryland. Dr. Carter has appeared on local, national, international television and radio to spread autism awareness and advocacy. In 2017, Dr. Carter provided training, seminars, and services to heighten autism awareness in Accra, Ghana. Dr. Carter has raised funds, coordinated and participated in 5k events for children diagnosed with autism. She raised a service dog to help aid in the life of child diagnosed with autism, and to date she raised and assisted in training CARAFAP’s therapy dog, Bailey to assist clients enrolled in CARAFAP’s services. She enjoys riding horses, reading, traveling, and spending time with her family.
Rhonda Spellman, CLT, AAP, began her search for better answers when her son was vaccine injured in 2001. Over 7,000 logged hours of research resulted in the publication of her third book, The Journey Home from Autism, winner of INDIE and EVVY awards, and a nomination into The Who’s Who in the Medical Industry by her pediatrician. She studied NAET, beginning in 2003; and added Low Level Laser Therapy to her private consultations in 2011. She became a Certified Laser Technician in 2017 and completed her studies to become an Allergy Antidote Practitioner, also in 2017. She uses a variety of energetic frequency devices to include a Rife Frequency Generator, PEMF and more. Her primary focuses include stabilizing emotional and physical pain, eliminating allergies and working with those on the autism spectrum. Rhonda owns Nourish Healthy Weight & Wellness Center, a clinic in Marshalltown, IA, USA. She is truly blessed by a team that includes two massage therapists, two skincare specialists, an aromatherapist and a Yoga instructor. Her past column, Beyond the Spectrum, appears on The Sleuth Journal. She has contributed to and/or keynoted conferences throughout the US and in Canada. More about her treatment options and clinic can be found at http://NourishHealthnet and http://RhondaSpellman.com
Dr. Huaizhong Hu serves currently as the general manager of the research institute at Beijing Konruns Pharmaceutical Company. Prior to Konruns Dr. Hu spent 10 years at Covance Laboratory and held senior scientific positions. Dr. Hu was a Lee Kuan Yew Research Fellow at the Department of Microbiology, National University of Singapore. He received his Medical Doctor Degree from West China University of Medical Sciences and subsequently his Ph.D. from Utrecht University, The Netherlands. He was a Postdoctoral Fellow in Immunology at the NIH where he successfully cloned and functionally evaluated a recombinant immunotoxin that has been developed and tested in Phase II clinical trial for skin T cell lymphoma. He has authored over 60 publications in peer-reviewed international biomedical journals, and is an inventor of over 30 U.S., Europe and China issued or pending patents.
Asmaa Mostafa Ahmed had pursued her bachelor and her Masters from Minia University Egypt, in the field of Biochemistry/Pharmacy on 15/05/2004 and 04/12/2007 respectively. She completed her Ph.D. on 24/03/2011 from Japan and she had served as a Demonstrator from 13/10/2004 to 23/01/2008, followed by Assistant Lecturer from 23/01/2008 to 22/08/2011 in Minia University/ PHARMACY/ Biochemistry. At present, she is a Lecturer in Minia University.
Hideo Nakayama was the Chief Dermatologist in Tokyo Saiseikai Central Hospital from 1970 to 1995. He was the Visiting Lecturer of Keio University, School of Medicine, from 1973 to 1995, Chief Dermatologist and Allergologist at Nakayama Dermatology Clinic from 1995 to 2015. He has graduated from Keio University, School of Medicine in 1961. Currently, he is the Advisor Doctor in Meguro Chen Dermatology Clinic (Tokyo). He has discovered new allergens, such as palladium,benzyl salicylate, R-219 (D&C R-31), ylang-ylang oil, ?-acaridial, etc., and developed new treatment systems by allergen control with pigmented cosmetic dermatitis, textile dermatitis, dental metal allergy and atopic dermatitis
Degenerative Processes, Stress and Aging
Dr. Poznansky is an innovator whose work bridges academic discovery and clinical care. As a leader in the field of leukocyte migration and the modulation of leukocyte trafficking and function, he has linked discovery with the generation of new vaccine and immunotherapeutic approaches in infectious diseases, cancer and type 1 diabetes. Dr. Poznansky has gained recognition for establishing a new model for translational research that accelerates the process by which basic biological discoveries move towards products and technologies that improve patient care and treatment. Since 2009 he has served as the director of the translational Vaccine and Immunotherapy Center (VIC) at MGH, which is putting this model into practice. The goal of VIC is to enable efficient and rapid transition of promising technologies through preclinical development and into the clinical stage of development through technology spin outs, partnerships or out-licensing. He oversees the research work of a team of investigators, postdoctoral fellows and other trainees addressing key research questions regarding these new therapeutics and vaccines, and leads an operational team that facilitates the execution of business, regulatory, manufacturing, and other developmental tasks associated with the preclinical translation of these candidates. Relevant to this presentation, Dr. Poznansky is the PI of a DTRA funded study to develop a novel vaccine for Q fever and directs a program at VIC which has developed three new immunotherapeutic approaches to the treatment of cancer including ovarian cancer and mesothelioma. His team leaders, including Dr. Jeff Gelfand and Dr. Satoshi Kashiwagi, direct the development of a program to develop a novel, safe and efficacious near infra-red light based adjuvant for both infectious disease and cancer vaccines. Dr. Poznansky obtained his B.Sc. and his MD at the University of Edinburgh and his PhD in Medical Sciences at Cambridge University. He also served as a Resident in Clinical Immunology at the Addenbrooke’s Hospital in Cambridge, UK and a Captain in the Royal Army Medical Corps (V). He completed his post-doctoral research training in retrovirology at Harvard Medical School and the Dana Farber Cancer Institute. He completed his infectious diseases fellowship training at Imperial College and Harvard Medical School. He is the scientific founder of three biotech companies and serves as the Co-Director of the Medicine Innovation Program at MGH.
William E. Feeman Jr., MD, is a Physician on staff at Wood County Hospital, and in private practice, both in Bowling Green, Ohio. He attended undergraduate school at Ohio State University (1961-1966) and became interested in a career in medicine during that time; prior to his decision to enter medicine he planned to have a career in astronomy. He attended undergraduate medical school at Ohio State University, earning Bachelor of Science in physiology (1961-1966) and medical school at Ohio State University (1966-1970); where he developed an interest in the primary and secondary prevention of atherothrombotic disease. Over the last 26 plus years, he has spent his professional life in medicine perfecting a tool to predict the population at risk of atherothrombotic disease e and to guide therapy to maximally stabilize/reverse that disease if extant. Thus he has founded the Bowling Green Study of the Primary and Secondary Prevention of Atherothrombotic Disease (BGS) to which he is the principal investigator. This study terminated on 4 November 2003. Dr. Feeman has had six major articles published in various science/medical journal. He has had numerous letters to the editor published in various medical journals. All publications relate to the primary and second prevention of atherothromboitc disease. He has presented data at a number of annual scientific assemblies of the American Academy of Family Physicians and at a number of national and international symposia in atherothrombotic disease. Dr. Feeman is the founder of the Association for the Prevention of Atherothrombotic Disease in Northwest Ohio to facilitate the spread of knowledge about this disease.
Antonietta M. Gatti, Ph.D. is the coordinator of the Italian Institute of Technology's Project of Nanoecotoxicology, called INESE. She is a selected expert of the FAO/WHO for the safety in nanotechnological food, and a Member of the NANOTOX Cluster of the European Commission. She is also the author of a book titled “Nanopathology: the health impact of nanoparticles,” and on the Editorial Board of Journal of Biomaterials Applications and a member of the CPCM of the Italian Ministry of Defense. She also founded a laboratory called Nanodiagnostics for the evaluation of the pathological tissues of patients. She is presently at the University of Modena and Reggio Emilia, Italy.
Tobias Innocent Ndubuisi Ezejiofor (a.k.a, T.I.N. Ezejiofor) was born on 21st January 1966 at Aba and hails from Amorka, Ihiala Local Government Area of Anambra State, Nigeria. He had his primary and secondary education at Aba between 1970 and 1975, 1975 and 1980 respectively. Thereafter, he proceeded to the School of Health Technology Aba, wherein 1983 he obtained the diploma in Environmental Health(DEH) of the institution as well as the Public Health diploma(DPH) of the West Africa Health Examination Board(WAHEB) thereby qualifying as a Public Health Officer. Beyond this, Mr Ezejiofor obtained a B.Sc. (Hons) degree in Medical Laboratory Sciences from Rivers State University of Science & Technology, Port Harcourt, Nigeria (1988), an M.Sc. degree in Applied Biochemistry from Nnamdi Azikiwe University, Awka, Nigeria (1997/98), and the degree of doctor of philosophy (PhD) in Environmental Health Biology from the Federal University of Technology, Owerri, Nigeria (2009/10). To cut his professional teeth, Dr. Ezejiofor also schooled at the University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria (1990) and the University of Nigeria Teaching Hospital, Enugu, Nigeria (1996) for the Associate and Fellowship of the Medical Laboratory Science Council of Nigeria in Chemical Pathology and Medical Microbiology respectively. He is duly registered and Licensed by both the Environmental Health Officers Registration Council of Nigeria (EHORECON) and the Medical Laboratory Science Council of Nigeria (MLSCN). He is also a Fellow, College of Biomedical Engineering and Technology (FCBET) of Nigeria; and Fellow, West Africa Postgraduate College of Environmental Health (FWAPCEH), as well as a member of several national and international professional and learned societies.
Environmental and Medical Biotechnology • Environmental epidemiology and burden of Infectious diseases in Nigeria • Medicinal properties and toxicology of indigenous plants and natural resources • Health Risks/Impacts of exposures to hazards /toxicants in the work / total environment • Development and validation of biomarkers of exposures and effects of various environmental agents • Waste to wealth: Environmental remediation/management strategies to turn wastes/pollutants into beneficial products or industrial raw materials for wealth creation Primary Teaching Area Medical and Environmental Biotechnology
Eslam Alshawadfy is working in Department of Dermatology research, National Research Centre, Egypt. Dr's research experience includes various programs, contributions and participation in different countries for diverse fields of study.
Dr. Sherry Bradford attended undergraduate school at SUNY at Buffalo and was awarded a full tuition scholarship to pursue her PhD graduate degree (Biochemistry) from the University of Buffalo/ Roswell Park Cancer Institute Division of SUNY at Buffalo School of Medical and Biomedical Sciences. During her clinical laboratory vocation, she was solicited by the Chief of Surgery at Millard Fillmore Hospital, Buffalo, NY, to direct the Surgical Research laboratory. There she successfully led the research on the use of human microvascular umbilical cord endothelium for lining stents. Besides her research, for the Chief of Staff, her responsibilities also included training ‘incoming” academic interns. It was while Sherry was at Millard Fillmore Hospital, that she was awarded the “1st Place - Award for Excellence in Research” from the American Federation for Clinical Research, and the “1st Place - Award for Excellence in Research” – SUNY at Buffalo, Roswell Park Cancer Institute Research Forum. In 1997, Dr. Bradford was approached by the Department of Pharmacokinetics, at Millard Fillmore Hospital, to lead their newly formed Pharmacokinetics Oncology Department. As the Principal Investigator, she was charged with the responsibility to develop an in vitro chemosensitivity test on tumor cells using the flow cytometer. In 2008, Dr Bradford and colleagues form AccuTheranostics and the idea od Oncology Personalized Medicine based on the specific patient’s own biochemical and genetic profile to administer personized treatment regimens. Currently, Dr. Bradford sits on the EDITORIAL BOARD of the International Journal of Medical and Health Sciences Research; on the EDITORIAL BOARD of Insights in Cancer Research, Editorial Board Member (Editor-in-Chief) for the Scientific Federation of Oncology & Cancer: Editorial Board Member of the Journal of Biomolecular Research and Therapy; and has authored and co-authored a number of scientific peer-reviewed manuscripts. She is also a member of many professional organizations including (but not limited to): International Metabolic Cancer Group, AACR, ASCO, and GLIFCA. She has been and will be an invited speaker at various domestic and international scientific meetings including: Invited Speaker: Proceedings of the 6th Int’l Conf on Frontiers of Polymers and Adv Materials, Recife, Brazil, March 2001; Key Note Speaker: Cancer Science 3rd World Congress Oct. 21, 2013 – San Francisco, CA; Plenary Speaker, Cancer Science 4th World Congress: Valencia, Spain, Sept. 1-3, 2015; International Expert and Key Note Speaker: INDO-GLOBAL HEALTHCARE SUMMIT & EXPO 2014, Hyderabad, India from July 23-26, 2015; Key Note Speaker: Dubai, United Arab Emirates, Aug 27-29, 2015; Keynote Speaker Gynecologic Oncology, May 19-21, 2016, San Antonio, Tx. This Year (2017) Keynote Speaker in Rome, Portugal, Dubai, Chicage, San Francisco and Philadelphia. Dr. Bradford also holds one patent: U.S. Patent No. 6485714, Published Patent - Serial No./Application No. 10/340,858, and 3 (2016) – patents pending (2016).
Diane Radford is a staff breast surgical oncologist with the Cleveland Clinic in Cleveland, Ohio, and Director of the Breast Program at Cleveland Clinic Hillcrest Hospital. Originally from Scotland, she trained on both sides of the Atlantic, including the Professorial Unit, Royal Infirmary of Edinburgh, the Western Infirmary, Glasgow, and St. Louis University. She has completed fellowships in Surgical Oncology (Roswell Park Cancer Institute) and Integrative Medicine (University of Arizona). Her peers have recognized her as a Best Doctor every year since 1996 as well as a Top Doctor nationally. She has authored numerous peer-reviewed journal articles and textbook chapters. Active on social media since 2011, she has lectured nationally and internationally on social media for health care professionals including at the Harvard course “Achieving Healthcare Leadership and Outcomes Through Writing, Publishing, and Social Media,” and at the American Society of Breast Surgeons annual meeting. She participates in the tweet chat #bcsm (breast cancer social media) and has been featured as a guest expert. She serves on the Editorial Board of the Annals of Surgical Oncology, Multi-Media section, and co-authored a guide for other members of the board on how to use Twitter. Her Twitter followers number over 15,000.